Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…Abstract Number: 402 • 2014 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?
Background/Purpose GP88 (progranulin; PGRN), a glycoprotein with a molecular weight of approximately 88000, is suggested to play an important role in the immune response and…Abstract Number: 365 • 2014 ACR/ARHP Annual Meeting
Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Background/Purpose DAS28 is an important outcome for clinical research and practice assisting with therapeutic decisions. The main contributors to DAS28 are joint tenderness and acute-phase…Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…Abstract Number: 2320 • 2013 ACR/ARHP Annual Meeting
Ultrasonographic Monitoring Of Response To Infliximab In Patients With Rheumatoid Arthritis
Background/Purpose: To evaluate the efficacy of treatment with infliximab on joint inflammation and bone erosion in rheumatoid arthritis (RA) patients using ultrasonography. Methods: 80 eligible…Abstract Number: 2223 • 2013 ACR/ARHP Annual Meeting
Monitoring Of Active Matrix Metalloproteinase-3 Using
Background/Purpose: Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active…Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…Abstract Number: 532 • 2013 ACR/ARHP Annual Meeting
Role Of Baseline C-Reactive Protein In Response To Infliximab Plus Naproxen Vs Naproxen Alone In Patients With Axial Spondyloarthritis
Background/Purpose: Baseline inflammation has been shown to influence response to tumor necrosis factor alpha antagonist treatment in patients with axial spondyloarthritis (SpA). This study evaluated…Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »